関: amrubicin hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/08/17 17:08:48」(JST)

wiki en

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.^[1] It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.^[2]

Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.^[3]^[4]

It has also been studied for the treatment of bladder carcinoma^[5] and gastric cancer.^[6]

Amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from Sumitomo.^[7]

References

^ Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]". Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.
^ Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17. ^{[dead link]}
^ Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10.
^ Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10.
^ Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]". Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.
^ Tsushima K, Sakata Y, Munakata A, et al. (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]". Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.
^ Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG. John Wiley & Sons, 2012 ISBN 9780470601815 P 106

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 難治性および再発性の小細胞肺癌の治療 treatment of refractory and relapsed small cell lung cancer
2. 抗腫瘍療法関連肺毒性：細胞傷害性薬物 pulmonary toxicity associated with antineoplastic therapy cytotoxic agents
3. 進展型小細胞肺癌：初期マネージメント extensive stage small cell lung cancer initial management

English Journal

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD1, Hahn NM2, Wong B3, Lee KM4, Argiriadi P4, Albany C5, Gimpel-Tetra K4, Lowe N4, Shahin M4, Patel V4, Tsao CK4, Oh WK4.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2015 Oct 13. [Epub ahead of print]
PURPOSE: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma.METHODS: Patients with progressive metastatic ur
PMID 26464352

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T1, Nokihara H1, Yoh K2, Niho S2, Goto K2, Ohmatsu H2, Kubota K3, Yamamoto N1, Sekine I4, Kunitoh H5, Fujiwara Y6, Ohe Y1.
Japanese journal of clinical oncology.Jpn J Clin Oncol.2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.
OBJECTIVE: Most of the previous studies of amrubicin in patients with previously treated small-cell lung cancer were conducted at a dose of 40 mg/m(2). The aim of this study was to assess the efficacy and safety of amrubicin at a dose of 45 mg/m(2) in patients with relapsed or refractory small-cell
PMID 26232449

Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.

Inomata M1, Hayashi R1, Tokui K1, Taka C1, Okazawa S1, Kambara K1, Ichikawa T1, Yamada T1, Miwa T1, Kashii T2, Matsui S1, Tobe K1.
Tumori.Tumori.2015 Sep 30;0(0):0. doi: 10.5301/tj.5000435. [Epub ahead of print]
AIMS AND BACKGROUND: Amrubicin monotherapy can be an effective treatment option for patients with recurrent small cell lung cancer (SCLC). We conducted this retrospective study to investigate the prognostic factors in patients with recurrent SCLC receiving amrubicin monotherapy.METHODS: The associat
PMID 26429641

Japanese Journal

A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer

Ikeda Takaya,Fukuda Minoru,Nakamura Yoichi,Kinoshita Akitoshi,Senju Hiroaki,Nakano Hirofumi,Kitazaki Takeshi,Ogawara Daiki,Taniguchi Hirokazu,Motoshima Kohei,Yamaguchi Hiroyuki,Nakatomi Katsumi,Shimada Midori,Nagashima Seiji,Tsukamoto Kazuhiro,Kohno Shigeru
Cancer Chemotherapy and Pharmacology 74(3), 497-502, 2014-09
… Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. … Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. … Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. …
NAID 120005511021

化学療法が奏効した前立腺小細胞癌の2例

浅井聖史,酒谷徹,水野桂 [他]
西日本泌尿器科 = The Nishinihon journal of urology 76(2), 39-43, 2014-02
NAID 40019985686

研究・症例小細胞肺癌のアムルビシン投与後に発症したリステリアによる敗血症性ショックの1救命例

築家直樹,池田宗一郎,高村香織 [他]
日本胸部臨床 73(1), 103-108, 2014-01
NAID 40019935542

「アムルビシン」

Amrubicin
Systematic (IUPAC) name
	(7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
Legal status
Legal status	℞ (Prescription only);
Identifiers
CAS Number	110267-81-7
ATC code	L01DB10 (WHO)
PubChem	CID 178149
ChemSpider	2299344
UNII	93N13LB4Z2
KEGG	D08854
ChEMBL	CHEMBL1186894
Chemical data
Formula	C25H25NO9
Molar mass	483.46 g/mol
	SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4 ;
	InChI InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 ; Key:VJZITPJGSQKZMX-XDPRQOKASA-N ;
(what is this?) (verify)